Praluzatamab is primarily used in targeted cancer therapies, particularly in the development of antibody-drug conjugates (ADCs). It binds specifically to ALCAM (CD166), a protein often overexpressed in various solid tumors, including breast, colorectal, and pancreatic cancers. This selective binding allows praluzatamab to deliver cytotoxic agents directly to cancer cells, minimizing damage to healthy tissues. Its application is especially valuable in oncology research and clinical settings where precision targeting enhances treatment efficacy and reduces side effects. Additionally, praluzatamab serves as a reference standard in immunoassays and flow cytometry to evaluate CD166 expression levels in tumor samples, supporting diagnostic and prognostic assessments.